Skip to NavigationSkip to content


Cancer Research UK partners with Biotecnol to deliver experimental solid tumour drug

Cancer Research UK (CRUK) has announced a collaboration with Biotecnol, an immuno-oncology firm focused on the development of multifunctional antibodies in areas of unmet need, to develop an experimental treatment for advanced solid tumours

The agreement between the two organisations means that Biotecnol will leverage CRUK’s expertise in drug development to push its therapy, known only as Tb535H, through its first in-man Phase 1 clinical trial, while CRUK will benefit from shareholdings in its partner.

AZ attempts to clear dust of Mystic trial with $8.5 billion MSD deal

It will be some time before the Mystic catastrophe hoo-ha dies down for AstraZeneca but it made a pre-emptive move to curtail coverage with a big announcement – the inking of an $8.5 billion deal with MSD (known as Merck in North America).

Celgene plays catch up with $1.4 billion immunotherapy deal

Those commentating on Celgene’s latest deal seem to be equally divided between two camps: it is too much money, too late, and those that think it might be a gamble that can pay off. The deal itself is a licensing agreement with BeiGene for its PD-1 immunotherapy, BGB-A317; it is structured so that BeiGene receives $263 million upfront, a further $150 million equity stake and close to $1 billion locked into milestone agreements.

FDA shutters MSD’s Keytruda combination trials in myeloma

Following on from the news last month that enrolment for Keytruda being used alongside Celgene’s Imnovid and Revlimid would have to be stopped, comes the complete halt called to three trials involving Keytruda.

American Cancer Society and Melanoma Research Alliance join forces to bring down immunotherapy side-effects

The American Cancer Society (ACS) and the Melanoma Research Alliance (MRA) have formed a research partnership to reduce the impact of rare but serious side-effects as a result of checkpoint inhibitor drugs in the treatment of cancer by improving patient outcomes and minimising toxicity.

The two organisations have agreed to commit $1 million each to the joint grant-making programme; $1 million will be used to support one large research project, while $200,000 will be given each to five others, primarily focusing on melanoma, among other cancer types.

BMS' Opdivo scores eighth approval in Europe for bladder cancer

Bristol-Myers Squibb has announced that its flagship immunotherapy treatment Opdivo (nivolumab) has secured its eighth approval in Europe as the European Commission accepts the drug for the treatment of locally-advanced unresectable or metastatic urothelial carcinoma (mUC) in adults following the failure of prior platinum-containing therapy.

T cells found to ‘acquire knowledge’ to take fight to metastatic cancer

T cells are widely known as being crucial in the fight against cancer within the body but little was known, previously, about what happened after their role was after infiltrating a tumour. In new research emerging from the Garvan Institute, the researchers were able to track the immune cells through the body after they had interacted with tumour cells to trace the T cells’ movements.

Introduction to Cancer: Focus on Solid Tumors

World Vaccine & Immunotherapy Congress West Coast

World Vaccine and Immunotherapy Congress West Coast

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches